Cognition Therapeutics (CGTX) Expected to Release Quarterly Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.07) per share and revenue of $5.30 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Cognition Therapeutics (NASDAQ:CGTX) last announced its earnings results on Thursday, August 6th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. On average, analysts expect Cognition Therapeutics to post ($0.30) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Cognition Therapeutics Stock Down 0.5%

NASDAQ CGTX traded down $0.00 during trading on Tuesday, hitting $0.71. The stock had a trading volume of 39,372 shares, compared to its average volume of 994,978. The company has a market capitalization of $67.14 million, a PE ratio of -4.15 and a beta of 1.80. The firm has a 50 day moving average price of $0.91 and a 200 day moving average price of $1.06. Cognition Therapeutics has a twelve month low of $0.55 and a twelve month high of $1.82.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CGTX. HC Wainwright reissued a “buy” rating on shares of Cognition Therapeutics in a research note on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, September 21st. Finally, Wall Street Zen downgraded shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.